There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Shellie-Anne Levy |
| Institution: | University of Florida |
| Department: | Clinical and Health Psychology |
| Country: | |
| Proposed Analysis: | Aim 1: To test the hypothesis that metabolic syndrome (MeSy) and its components will be associated with declines in global cognition, memory, and executive functioning, but not language or visuospatial functioning. Aim 2: To test the hypothesis that MeSy and its components will be associated with greater risk for incident vascular dementia and Alzheimer’s disease. Aim 3: To test the hypothesis that MeSy and its components will be associated with greater risk for vascular pathology (micro-and macro-infarcts, atherosclerosis, and hippocampal sclerosis), Alzheimer’s pathology (Braak stage, CERAD level, and quantitative regional measures of tau and amyloid), and Lewy bodies. Analyses will be stratified by race to examine differential racial outcomes in cognition and pathology. |
| Additional Investigators | |
| Investigator's Name: | Paul Crane |
| Proposed Analysis: | Aim 1: To test the hypothesis that metabolic syndrome (MeSy) and its components will be associated with greater longitudinal declines in global cognition, memory, and executive functioning, but not language or visuospatial functioning. To address the effects of physical vitality, we will specifically consider performance on the Short Portable Physical Battery (SPPB) to test the hypothesis that people with MeSy and high physical performance will have better cognitive outcomes than people with MeSy and impaired physical performance. Aim 2: To test the hypothesis that MeSy and its components will be associated with greater risk for incident vascular dementia and Alzheimer’s disease. We will also determine whether the proportions of people in different cognitively-defined Alzheimer’s disease subgroups is similar across people with and without a history of MeSy. Aim 3: To test the hypothesis that MeSy and its components will be associated with greater risk for vascular pathology (micro-and macro-infarcts, atherosclerosis, and hippocampal sclerosis), Alzheimer’s pathology (Braak stage, CERAD level, and quantitative regional measures of tau and amyloid), and Lewy bodies. We will perform all of analyses in the entire cohort and, where numbers allow, we will perform analyses stratified by race. |
